<DOC>
	<DOCNO>NCT00000808</DOCNO>
	<brief_summary>To determine bioavailability , pharmacokinetics , short-term safety tolerance nevirapine HIV-1 infect pregnant woman newborns nevirapine give mother active labor , neonate dose first week life . To determine short-term safety profile mother receive zidovudine ( AZT ) receive nevirapine active labor , neonates receive dose , single dose , multiple dos nevirapine receive AZT first 6 week life . Treatment HIV-1 infect pregnant woman active labor may result therapeutic level nevirapine neonate time exposure HIV-1 parturition , decrease neonate 's risk infection .</brief_summary>
	<brief_title>A Phase I Study Safety Pharmacokinetics Nevirapine HIV-1 Infected Pregnant Women Neonates Born HIV-1 Infected Mothers</brief_title>
	<detailed_description>Treatment HIV-1 infect pregnant woman active labor may result therapeutic level nevirapine neonate time exposure HIV-1 parturition , decrease neonate 's risk infection . Pregnant woman active labor receive single dos oral nevirapine . The neonate first 4-6 ( PER AMENDMENT 8/27/96 , 4 ) mother receive drug , neonates second 4-6 ( PER AMENDMENT 8/27/96 , 4 ) patient cohort receive single dose nevirapine . If neonatal antiviral level nevirapine sustain 7 day single dose , third cohort 4-6 ( PER AMENDMENT 8/27/96 , 4 ) pregnant woman receive single dose nevirapine neonate receive multiple dos nevirapine maintain antiviral effect 7 day .</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Nevirapine</mesh_term>
	<criteria>Inclusion Criteria Concurrent Medication : Allowed : AZT ( mother neonate ) . Oral asthma inhaler ( mother ) . Concurrent Treatment : Allowed : Phototherapy ( neonate ) . MOTHERS must : HIV infection . Estimated gestational age &gt; = 34 week . No active opportunistic infection study entry . PER AMENDMENT 8/27/96 : A preenrollment plasma HIV1 RNA level great 10,000 copies/ml . Exclusion Criteria Coexisting Condition : MOTHERS follow symptoms condition exclude : Intrauterine growth retardation . Fetal anomaly incompatible life determine preentry ultrasound . Participation current pregnancy therapeutic vaccine perinatal trial . Known hypersensitivity benzodiazepine . Serious bacterial infection . Concurrent Medication : Excluded : Any antiretroviral AZT . Corticosteroids ( oral asthma inhaler ) . Anticoagulants . Any clavulanic acidcontaining formulation ( e.g. , Augmentin , Timentin ) . Benzodiazepines study drug . Phenobarbital . Barbiturates . Antacids . Magnesium sulfate . Prior Medication : Excluded : Prior nevirapine . Current use illicit substance and/or active chronic alcohol use .</criteria>
	<gender>Female</gender>
	<minimum_age>13 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>March 2012</verification_date>
	<keyword>Pregnancy</keyword>
	<keyword>Pregnancy Complications , Infectious</keyword>
	<keyword>Acquired Immunodeficiency Syndrome</keyword>
	<keyword>AIDS-Related Complex</keyword>
	<keyword>Nevirapine</keyword>
</DOC>